Compare DAC & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAC | CRVS |
|---|---|---|
| Founded | 1972 | 2014 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2006 | 2016 |
| Metric | DAC | CRVS |
|---|---|---|
| Price | $105.72 | $19.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $105.00 | $28.00 |
| AVG Volume (30 Days) | 74.8K | ★ 7.7M |
| Earning Date | 02-09-2026 | 03-24-2026 |
| Dividend Yield | ★ 3.43% | N/A |
| EPS Growth | ★ 2.73 | N/A |
| EPS | ★ 26.76 | N/A |
| Revenue | ★ $1,042,456,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.92 | ★ N/A |
| Revenue Growth | ★ 2.79 | N/A |
| 52 Week Low | $65.40 | $2.54 |
| 52 Week High | $107.60 | $26.95 |
| Indicator | DAC | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 67.89 | 59.28 |
| Support Level | $99.99 | $18.92 |
| Resistance Level | $107.60 | $21.57 |
| Average True Range (ATR) | 2.36 | 1.73 |
| MACD | 0.09 | -0.53 |
| Stochastic Oscillator | 76.87 | 10.30 |
Danaos Corp is an international owner of containerships. It provides international seaborne transportation services by operating vessels in the containership sector of the shipping industry. The company's customers include, HMM, MSC, Yang Ming, Hapag Lloyd, ZIM, Maersk, COSCO, OOCL, ONE, PIL, Sealead, Niledutch, Samudera, OSC, and Arkas. Geographically, the company operates in Australia-Asia, Europe, and America, with maximum revenue from the Australia-Asia region. It has two reporting segments Container vessels and Drybulk vessels segment. It generates the majority of its revenue from Container vessels.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).